Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 14, 2006 Stephen Albainy-Jenei	Merck Gets Punk'd by Thailand Thailand issues a compulsory license to manufacture a generic version of Merck's patented AIDS drug. This is an act of humanitarian aid, but it is also an avenue for price and profit erosion worldwide.
The Motley Fool January 31, 2007 Brian Lawler	You're Only Hurting Yourself, Thailand Thailand's decision to allow generics could do more harm than good. Investors, take note.
The Motley Fool March 20, 2007 Brian Lawler	Smart Move by Abbott? Abbott takes a drastic measure to make a point about its patents. Thailand's actions offer a good warning of what can happen when governments try to intervene too much in existing markets.
Salon.com June 1, 2001 Daryl Lindsey	The AIDS-drug warrior Outspoken AIDS-drug activist Jamie Love says pharmaceutical companies must be forced to yield their patents to save hundreds of thousands of lives. Is he a visionary -- or a dangerous radical?
Chemistry World February 15, 2007 Victoria Gill	Novartis Contests India's Patent Law Swiss pharmaceutical company Novartis has accused the Indian government of failing to comply with WTO rules after it refused to grant the company a patent on its cancer drug Glivec.
Chemistry World January 21, 2013 Andy Extance	India pushes for emergency drug licenses The Indian government is preparing to grant compulsory licenses allowing three patented cancer drugs to be produced in the country and sold at reduced rates without permission from the patent owners.
Chemistry World July 11, 2012 Ling Wang	China Targets Patented Drugs with Law Change China has altered its licensing laws to allow domestic pharmaceutical companies to make cheap generic copies of patented drugs under certain circumstances.
Chemistry World March 20, 2012 Rajesh Parishwad	India Green Lights Production of Patented Cancer Drug For the first time India has invoked a 'compulsory license' clause to cut the cost of a patented anti-cancer drug by allowing another company to manufacture the therapy.
Salon.com March 19, 2001 Ben Barber	Fighting the plague The World Trade Organization steps into Africa's AIDS crisis, creating incentives for pharmaceutical companies to give some of their drugs away.
Salon.com May 1, 2001 Daryl Lindsey	Amy and Goliath A first-year law student brought a giant pharmaceutical to its knees. But will her victory for South Africa's AIDS sufferers deprive the world of new medicines?
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool April 26, 2007 Brian Lawler	Brazil's Boneheaded Drug Move Brazil already receives a steep discount on the price that Merck charges it for its HIV compounds. Nevertheless, it wants still lower prices to help reduce the government's costs associated with supplying drugs to those living with HIV/AIDS.
BusinessWeek August 5, 2010 Bennett & Randall	AIDS Drugs Flow to the Third World Drugmakers, once blasted for their practices, are slashing prices and licensing AIDS drugs for free to nonprofits or local manufacturers in developing countries.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
Pharmaceutical Executive October 1, 2011 Amrita Ghaswalla	Changing the Dialogue No industry leader is more closely associated with the goal of seeding the globe with low-cost generics than Mumbai-based Cipla Chairman Y.K. Hamied.
The Motley Fool September 28, 2010 Brian Orelli	Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool August 30, 2010 Brian Orelli	Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help.
Chemistry World August 23, 2012 Dean Baker	Monopoly money It is remarkable that the system of patent support for prescription drug research has not become more of a policy issue.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
The Motley Fool February 2, 2010 Brian Orelli	Shaking Up the Biotech Industry A judge will decide if genes are patentable or not.
BusinessWeek April 18, 2005 Manjeet Kripalani	India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.
The Motley Fool January 26, 2011 Brian Orelli	Health-Care Reform Lives: Here's Where to Invest State of the Union turned investment thesis regarding health insurance companies.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
Chemistry World May 21, 2009 Matt Wilkinson	Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
The Motley Fool August 26, 2010 Brian Orelli	Drug Prices Up, but Don't Read Too Much Into It AARP is out with its annual report on the cost of medications, and it's more of the same: bad news if you're a consumer, but good news if you're invested in drugmakers.
Pharmaceutical Executive November 1, 2005 Tamsen Valoir	Legal: State Compulsory Licenses The Supreme Court extended the power of eminent domain. Now states want to issue compulsory licenses under the same principle to control drug prices.
The Motley Fool May 28, 2010 Brian Orelli	Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree.
BusinessWeek June 24, 2010 Bliss & Decker	Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete.
Pharmaceutical Executive September 1, 2006 Kieran Hartsough	Benchmarking AIDS Pharma is taking on the global AIDS crisis. But who has crafted the best approach? The Interfaith Center on Corporate Responsibility defines best practices and matches major companies head-to-head. Grades are posted inside.
Pharmaceutical Executive April 1, 2014 Subramanian et al.	"Market-Based" Price Controls In India? Three strategic implications for pharma pricing strategies in India.
Reason February 2002 Mike Godwin	Prescription Panic How the anthrax scare challenged drug patents...
The Motley Fool December 1, 2011 John Grgurich	Pfizer Losing Lipitor Patent: What Investors Need to Know The patent ends today.
The Motley Fool June 7, 2011 Brian Orelli	Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal.
The Motley Fool February 11, 2010 Brian Orelli	A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid.
The Motley Fool February 26, 2010 Brian Orelli	A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus.
The Motley Fool March 31, 2010 Brian Orelli	When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies.
The Motley Fool July 16, 2009 Brian Orelli	A Strong Dollar Can Hurt Novartis makes it through a hard quarter.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
Chemistry World October 29, 2007 Arthur Rogers	Deal to Allow Poor Nations Better Access to Cheap Drugs MEPs belatedly approved EU ratification of a 2005 World Trade Organization protocol on compulsory licensing -- potentially paving the way for developing countries to order generic drugs from manufacturers abroad without infringing patent rights.
The Motley Fool January 26, 2009 Brian Orelli	Have Drugs, Will Travel After buying Bristol-Myers Squibb's businesses in Egypt and Pakistan, GlaxoSmithKline is now off to Africa.
The Motley Fool June 30, 2009 Brian Orelli	A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention.
BusinessWeek June 16, 2011 Langreth & Cortez	When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates.
The Motley Fool April 27, 2006 Stephen D. Simpson	A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.